Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence

More on GLP-1 and incretin signalling

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026